Claims
- 1. A compound of the formula: wherein,X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C3-C10)cycloalkyl, aroyl, (C2-C18)alkanoyl, (C1-C18)alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; A is —C(═O)—, —C(═S)—, —C(═CH2)—, —C(═O)CH2—, —CH2CH2—, —CR26═N—, or —CR25R16—; R25 is hydrogen, (C1-C6)alkyl, hydroxy, or (C1-C8)alkanoyloxy; R26 is hydrogen or (C1-C6)alkyl; either one of By and Bz is CH or N and the other is CH; U is O or S; q is 1, 2, 3, or 4; R1 is —CR24R27-(CR23R24)n—CR24R27— where n is 0, 1, 2, or 3; or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24—, or —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18) linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkoxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined, and wherein aryl is as defined hereinafter; and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is as previously defined, and p is as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; and R4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C1-C6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C1-C18)acyl amino, (C1-C18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C18 straight or branched chain)alkyl or —C(═O)-aryl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamine dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; with the proviso that R23 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, or with the proviso that R24 is not hydrogen, (C1-C18)linear alkyl, phenyl, or when R27 is hydrogen and n is 0; or when R27 is hydrogen and R23 is hydrogen, (C1-C18)linear alkyl, phenyl, or or when R1 is —CHR24—CH═CH—CHR24— or —CHR24—C≡C—CHR24—; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)carboxylic (C4-C18)alkanoyl group, ; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; and q is 1, 2, 3, or 4; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 2. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.
- 3. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 1.
- 4. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier.
- 5. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1.
- 6. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains an acylated hydroxy group, or an acylated amino group.
- 7. The depot pharmaceutical composition of claim 6, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 8. The composition of claim 6, which contains a pharmaceutically acceptable oil.
- 9. The composition of claim 8, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 10. The composition of claim 7, which contains a pharmaceutically acceptable oil.
- 11. The composition of claim 10, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 12. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 6 sufficient to produce a long acting antipsychotic effect.
- 13. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 7 sufficient to produce a long acting antipsychotic effect.
- 14. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 11 sufficient to produce a long acting antipsychotic effect.
- 15. A compound of the formula: wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups, wherein aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy or halogen, when p is 2 and X is —O—; q is 1, 2, 3, or 4; in which (R1) is R20, R21 or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—CH≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH═CH—CH2—, —CH2—CH≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, mono- or dialkylamino, C1-C3 acyl amino, C1-C6 alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C12 straight or branched chain) alkyl or —C(═O)-aryl; in which aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 16. A pharmaceutical composition which comprises a compound of claim 15 and a pharmaceutically acceptable carrier therefor.
- 17. An antipsychotic composition, which comprises the compound of claim 15 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.
- 18. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 15.
- 19. An analgesic composition, which comprises the compound of claim 15 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier.
- 20. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 15.
- 21. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula: wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups, wherein aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy or halogen, when p is 2 and X is —O—; q is 1, 2, 3, or 4; in which (R1) is R20, R21 or R22, wherein: R20 is —(CH2)n—, where n is 2, 3, 4 or 5; R21 is —CH2—CH═CH—CH2—, —CH2—CH≡C—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH═CH—CH2—, —CH2—CH≡C—CH2—CH2—, or —CH2—CH2—C≡C—CH2—, the —CH═CH— bond being cis or trans; R22 is R20 or R21 in which one or more carbon atoms of R20 or R21 are substituted by at least one C1-C6 linear alkyl group, phenyl group or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2 or halogen, and p is as previously defined; and R4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, mono- or dialkylamino, C1-C3 acyl amino, C1-C6 alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C12 straight or branched chain) alkyl or —C(═O)-aryl; in which aryl is phenyl or where R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof.
- 22. The composition of claim 21, which contains a pharmaceutically acceptable oil.
- 23. The composition of claim 22, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 24. The depot pharmaceutical composition of claim 21, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 25. The composition of claim 24, which contains a pharmaceutically acceptable oil.
- 26. The composition of claim 25, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 27. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 21 sufficient to produce a long acting antipsychotic effect.
- 28. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 23 sufficient to produce a long acting antipsychotic effect.
- 29. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 26 sufficient to produce a long acting antipsychotic effect.
- 30. A compound of the formula: wherein X is —O—, —S—, —NH—, or —N(R2)—; R2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C3-C10)cycloalkyl, aroyl, (C2-C18)alkanoyl, (C1-C18)alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 2; Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethoxy, nitro or amino when X is —S—, —NH—, or —N(R2)—; Y is lower alkyl, trifluoromethoxy, nitro or amino when X is —O—; A is —C(═O)—, —C(═S)—, —C(═CH2)—, —C(═O)CH2—, —CH2CH2—, —CR26═N—, or —CR25R26—; R25 is hydrogen, (C1-C6)alkyl, hydroxy, or (C1-C8)alkanoyloxy; R26 is hydrogen or (C1-C6)alkyl; either one of By and Bz is CH or N and the other is CH; U is O or S; q is 1, 2, 3, or 4; R1 is —CR24R27—(CR23R24)n—CR24R27—, where n is 0, 1, 2, or 3; or —CHR24—CH═CH—CHR24—, —CHR24—C≡C—CHR24—, —CHR24—CH═CH—CR23R24—CHR24—, —CHR24—CR23R24—CH═CH—CHR24—, —CHR24—C≡C—CR23R24—CHR24, or —CHR24—CR23R24—C≡C—CHR24—, the —CH═CH— bond being cis or trans; R23 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy, (C1-C18)alkoxy, aryloxy, aryl(C1-C18)alkyloxy, (C1-C18)alkanoyloxy, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is lower alkyl, —OH, lower alkoxy, —CF3, —NO2, —NH2, or halogen, and p is as previously defined, and wherein aryl is as defined hereinafter; and R24 is hydrogen, (C1-C18)linear alkyl, phenyl, hydroxy(C1-C6)alkyl, (C1-C18)alkoxy(C1-C6)alkyl, phenyl(C1-C6)alkyloxy, aryl(C1-C18)alkyloxy(C1-C6)alkyl, (C1-C18)alkanoyloxy(C1-C6)alkyl, or where Z1 is as previously defined, and p is as previously defined; R27 is hydrogen or R24 and R27 taken together with the carbon to which they are attached form C═O or C═S; and R4 is hydrogen, lower alkyl, lower alkoxy, hydroxy, tri(C1-C6)alkylsilyloxy, hydroxy lower alkyl, alkanoyloxy lower alkyl, amino, mono- or dialkylamino, (C1-C18)acyl amino, (C1-C18)alkanoyl, trifluoromethyl, chlorine, fluorine, bromine, —O—C(═O)—(C1-C18 straight or branched chain)alkyl or —C(═O)-aryl; in which aryl is phenyl or wherein R5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C4-C18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C4-C18)alkoxycarbonyl group; all geometric, optical, and stereoisomers thereof; or a pharmaceutically acceptable acid addition salt thereof.
- 31. An antipsychotic composition, which comprises the compound of claim 30 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier.
- 32. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 30.
- 33. An analgesic composition, which comprises the compound of claim 30 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier.
- 34. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 30.
- 35. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 30, wherein the compound contains an acylated hydroxy group, or an acylated amino group.
- 36. The depot pharmaceutical composition of claim 35, wherein the hydroxy goup is acylated with a (C4-C18)alkanoyl group, or the amino group is acylated with a (C4-C18)alkanoyl group of a (C4-C18)alkoxycarbon group.
- 37. The composition of claim 35, which contains a pharmaceutically acceptable oil.
- 38. The composition of claim 37, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 39. The composition of claim 36, which contains a pharmaceutically acceptable oil.
- 40. The composition of claim 39, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols.
- 41. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 36 sufficient to produce a long acting antipsychotic effect.
- 42. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 38 sufficient to produce a long acting antipsychotic effect.
- 43. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 40 sufficient to produce a long acting antipsychotic effect.
CROSS-REFERENCE TO RELATED APPLICATION
This is a division of pending application Ser. No. 08/329,000 filed Oct. 25, 1994 of Joseph T. Strupczewski, Grover C. Helsley, Edward J. Glamkowski, Yulin Chiang, Kenneth J. Bordeau, Peter A. Nemoto and John J. Tegeler for HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS, U.S. Pat. No. 5,776,963, which is a continuation-in-part application of Ser. No. 08/144,265, filed Oct. 28, 1993, now abandoned, which is a continuation-in-part application of Ser. No. 07/969,383, filed Oct. 30, 1992, now U.S. Pat. No. 5,364,866 which is a continuation-in-part application of Ser. No. 07/788,269, filed Nov. 5, 1991, now abandoned, which is a continuation-in-part application of Ser. No. 07/944,705, filed Sep. 5, 1991, now abandoned, which is a continuation application of Ser. No. 07/619,825, filed Nov. 29, 1990, now abandoned, which is a continuation application of Ser. No. 07/456,790, filed Dec. 29, 1989, now abandoned, which is a continuation-in-part application of Ser. No. 07/354,411, filed May 19, 1989, now abandoned. The entire disclosure of these applications is relied upon and incorporated by reference herein.
US Referenced Citations (14)
Foreign Referenced Citations (23)
Number |
Date |
Country |
353 0089 |
Mar 1986 |
DE |
2 503 816 |
Jul 1975 |
DK |
0 013 612 |
Jul 1980 |
EP |
0 135 781 |
Apr 1985 |
EP |
0 196 096 |
Oct 1986 |
EP |
0 261 688 |
Mar 1988 |
EP |
0 302 423 |
Feb 1989 |
EP |
0 314 098 |
May 1989 |
EP |
0 329 168 |
Aug 1989 |
EP |
0 353 821 |
Feb 1990 |
EP |
0 357 134 A1 |
Mar 1990 |
EP |
0 398 425 |
Nov 1990 |
EP |
0 402 644 |
Dec 1990 |
EP |
0 464 846 |
Jan 1992 |
EP |
0 542 136 A1 |
May 1993 |
EP |
2 163 432 |
Feb 1986 |
GB |
233 710 |
May 1990 |
NZ |
233 503 |
Jun 1991 |
NZ |
233 525 |
Sep 1991 |
NZ |
PCT WO9309012 |
May 1993 |
WO |
PCT WO9316073 |
Aug 1993 |
WO |
WO 9316703 |
Aug 1993 |
WO |
PCT WO9418196 |
Aug 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fuller, R.W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd., 1982, pp. 221-247. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08/471574 |
Jun 1995 |
US |
Child |
09/185968 |
|
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
07/619825 |
Nov 1990 |
US |
Child |
07/944705 |
|
US |
Parent |
07/456790 |
Dec 1989 |
US |
Child |
07/619825 |
|
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
08/144265 |
Oct 1993 |
US |
Child |
08/329000 |
|
US |
Parent |
07/969383 |
Oct 1992 |
US |
Child |
08/144265 |
|
US |
Parent |
07/788269 |
Nov 1991 |
US |
Child |
07/969383 |
|
US |
Parent |
07/944705 |
Sep 1991 |
US |
Child |
07/788269 |
|
US |
Parent |
07/354411 |
May 1989 |
US |
Child |
07/456790 |
|
US |
Reissues (1)
|
Number |
Date |
Country |
Parent |
08/471574 |
Jun 1995 |
US |
Child |
09/185968 |
|
US |